Continuous Microfluidic Production of Citrem-Phosphatidylcholine Nano-Self-Assemblies for Thymoquinone Delivery.
inverse bicontinuous cubic Pn3m phase
microfluidics
nanoparticle tracking analysis
synchrotron small-angle scattering
thymoquinone
Journal
Nanomaterials (Basel, Switzerland)
ISSN: 2079-4991
Titre abrégé: Nanomaterials (Basel)
Pays: Switzerland
ID NLM: 101610216
Informations de publication
Date de publication:
07 Jun 2021
07 Jun 2021
Historique:
received:
18
05
2021
revised:
04
06
2021
accepted:
05
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
3
7
2021
Statut:
epublish
Résumé
Lamellar and non-lamellar liquid crystalline nanodispersions, including liposomes, cubosomes, and hexosomes are attractive platforms for drug delivery, bio-imaging, and related pharmaceutical applications. As compared to liposomes, there is a modest number of reports on the continuous production of cubosomes and hexosomes. Using a binary lipid mixture of citrem and soy phosphatidylcholine (SPC), we describe the continuous production of nanocarriers for delivering thymoquinone (TQ, a substance with various therapeutic potentials) by employing a commercial microfluidic hydrodynamic flow-focusing chip. In this study, nanoparticle tracking analysis (NTA) and synchrotron small-angle X-ray scattering (SAXS) were employed to characterize TQ-free and TQ-loaded citrem/SPC nanodispersions. Microfluidic synthesis led to formation of TQ-free and TQ-loaded nanoparticles with mean sizes around 115 and 124 nm, and NTA findings indicated comparable nanoparticle size distributions in these nanodispersions. Despite the attractiveness of the microfluidic chip for continuous production of citrem/SPC nano-self-assemblies, it was not efficient as comparable mean nanoparticle sizes were obtained on employing a batch (discontinuous) method based on low-energy emulsification method. SAXS results indicated the formation of a biphasic feature of swollen lamellar (L
Identifiants
pubmed: 34200457
pii: nano11061510
doi: 10.3390/nano11061510
pmc: PMC8229635
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Teknologi og Produktion, Det Frie Forskningsråd
ID : reference DFF-7017-00065
Organisme : Natur og Univers, Det Frie Forskningsråd
ID : Danscatt
Références
Langmuir. 2012 Aug 14;28(32):11755-66
pubmed: 22831645
Food Funct. 2014 Jul 25;5(7):1409-21
pubmed: 24777447
Iran J Basic Med Sci. 2014 Dec;17(12):950-7
pubmed: 25859298
Anticancer Res. 2011 Mar;31(3):771-6
pubmed: 21498694
Eur J Pharm Sci. 2017 Apr 1;101:31-42
pubmed: 28137471
J Colloid Interface Sci. 2021 Apr;587:90-100
pubmed: 33360913
Pharm Res. 2005 Dec;22(12):2163-73
pubmed: 16267633
Phys Chem Chem Phys. 2019 Jul 10;21(27):15142-15150
pubmed: 31243413
J Control Release. 2010 Jan 4;141(1):62-9
pubmed: 19716852
Int J Pharm. 2018 Oct 25;550(1-2):57-70
pubmed: 30121331
Adv Colloid Interface Sci. 2009 Mar-Jun;147-148:333-42
pubmed: 18804754
J Phys Chem Lett. 2016 Sep 1;7(17):3482-6
pubmed: 27541048
Langmuir. 2018 Jun 5;34(22):6570-6581
pubmed: 29768016
Ther Deliv. 2019 Feb;10(2):113-132
pubmed: 30678550
ACS Omega. 2018 Mar 31;3(3):3235-3247
pubmed: 30023865
Drug Deliv. 2012 Nov;19(8):371-7
pubmed: 23043626
J Control Release. 2016 Oct 10;239:1-9
pubmed: 27524284
Curr Med Chem. 2017;24(5):470-482
pubmed: 27538694
Biomaterials. 2000 Feb;21(3):223-34
pubmed: 10646938
ACS Nano. 2018 Sep 25;12(9):9196-9205
pubmed: 30081623
Biomaterials. 2013 Nov;34(33):8491-503
pubmed: 23932247
Chem Phys Lipids. 2018 Nov;216:30-38
pubmed: 30222973
Langmuir. 2019 Jun 18;35(24):7954-7961
pubmed: 31150248
J Am Chem Soc. 2004 Mar 10;126(9):2674-5
pubmed: 14995164
Nanomedicine. 2015 Nov;11(8):1909-14
pubmed: 26348655
Expert Opin Drug Deliv. 2020 Dec;17(12):1781-1805
pubmed: 32886531
Mol Pharm. 2009 Sep-Oct;6(5):1333-42
pubmed: 19552481
Phys Chem Chem Phys. 2019 Jun 28;21(24):13005-13013
pubmed: 31165825
Front Cell Dev Biol. 2021 Feb 11;9:617984
pubmed: 33644054
Ther Deliv. 2015;6(12):1347-64
pubmed: 26652281
J Mol Biol. 1964 May;8:660-8
pubmed: 14187392
Phys Chem Chem Phys. 2017 Sep 13;19(35):23690-23703
pubmed: 28828415
Pharmaceutics. 2020 Nov 15;12(11):
pubmed: 33203082
Molecules. 2019 Dec 19;25(1):
pubmed: 31861549
J Colloid Interface Sci. 2021 Jan 15;582(Pt B):906-917
pubmed: 32919118
Mol Pharm. 2015 Dec 7;12(12):4214-25
pubmed: 26505213
Acta Pharm Sin B. 2021 Apr;11(4):871-885
pubmed: 33996404
Langmuir. 2010 Jun 1;26(11):8559-66
pubmed: 20146467
Phys Chem Chem Phys. 2021 Feb 19;23(6):3693-3706
pubmed: 33533338
Analyst. 2017 Aug 21;142(17):3118-3126
pubmed: 28744529
Expert Opin Drug Deliv. 2015 Apr;12(4):547-62
pubmed: 25345543
Macromol Biosci. 2019 Nov;19(11):e1900182
pubmed: 31609099
Sci Rep. 2021 Jan 8;11(1):72
pubmed: 33420136
Molecules. 2019 Aug 22;24(17):
pubmed: 31443533
J Phys Chem Lett. 2017 Jan 5;8(1):73-79
pubmed: 27936765
Adv Drug Deliv Rev. 2018 Mar 15;128:84-100
pubmed: 29567396
Langmuir. 2017 Dec 12;33(49):14045-14057
pubmed: 29136473
Expert Opin Drug Deliv. 2014 Apr;11(4):547-64
pubmed: 24490701
Adv Colloid Interface Sci. 2017 Nov;249:331-345
pubmed: 28477868
ACS Appl Mater Interfaces. 2019 Jan 23;11(3):2821-2829
pubmed: 30589253
Drug Deliv Transl Res. 2019 Feb;9(1):404-413
pubmed: 30306459
ACS Nano. 2010 Apr 27;4(4):2077-87
pubmed: 20356060
ACS Nano. 2019 Jun 25;13(6):6178-6206
pubmed: 31082192
J Colloid Interface Sci. 2021 Feb 1;583:672-682
pubmed: 33039864
Colloids Surf B Biointerfaces. 2021 May;201:111633
pubmed: 33639513